7pbe › Citations

Emergence of immune escape at dominant SARS-CoV-2 killer T cell epitope.
<div class='caption-title'>SARS-CoV-2 variation in the immunodominant YLQPRTFLL dominant HLA A02-restricted CD8 T cell epitope</div>
<div class='caption-title'>SARS-CoV-2 viral dynamics of P272L Spike mutation in Western Europe</div>
Dolton G, Rius C, Hasan MS, Wall A, Szomolay B, Behiry E, Whalley T, Southgate J, Fuller A, Morin T, Topley K, Tan LR, Goulder PJR, Spiller OB, Rizkallah PJ, Jones LC, Connor TR, Sewell AK
OpenAccess logo Cell 185 2936-2951.e19 (2022)
Related entries: 7p3d, 7p3e

Cited: 55 times
EuropePMC logo PMID: 35931021

Abstract

We studied the prevalent cytotoxic CD8 T cell response mounted against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Spike glycoprotein269-277 epitope (sequence YLQPRTFLL) via the most frequent human leukocyte antigen (HLA) class I worldwide, HLA A∗02. The Spike P272L mutation that has arisen in at least 112 different SARS-CoV-2 lineages to date, including in lineages classified as "variants of concern," was not recognized by the large CD8 T cell response seen across cohorts of HLA A∗02+ convalescent patients and individuals vaccinated against SARS-CoV-2, despite these responses comprising of over 175 different individual T cell receptors. Viral escape at prevalent T cell epitopes restricted by high frequency HLAs may be particularly problematic when vaccine immunity is focused on a single protein such as SARS-CoV-2 Spike, providing a strong argument for inclusion of multiple viral proteins in next generation vaccines and highlighting the need for monitoring T cell escape in new SARS-CoV-2 variants.

Reviews - 7pbe mentioned but not cited (1)

  1. Seeing the T cell Immunity of SARS-CoV-2 and SARS-CoV: Believing the Epitope-Oriented Vaccines. Yue C, Wang P, Tian J, Gao GF, Liu K, Liu WJ. Int J Biol Sci 19 4052-4060 (2023)

Articles - 7pbe mentioned but not cited (3)



Reviews citing this publication (17)

  1. The biological and clinical significance of emerging SARS-CoV-2 variants. Tao K, Tzou PL, Nouhin J, Gupta RK, de Oliveira T, Kosakovsky Pond SL, Fera D, Shafer RW. Nat Rev Genet 22 757-773 (2021)
  2. SARS-CoV-2 variant biology: immune escape, transmission and fitness. Carabelli AM, Peacock TP, Thorne LG, Harvey WT, Hughes J, COVID-19 Genomics UK Consortium, Peacock SJ, Barclay WS, de Silva TI, Towers GJ, Robertson DL. Nat Rev Microbiol 21 162-177 (2023)
  3. The evolution of SARS-CoV-2. Markov PV, Ghafari M, Beer M, Lythgoe K, Simmonds P, Stilianakis NI, Katzourakis A. Nat Rev Microbiol 21 361-379 (2023)
  4. The Evolution and Biology of SARS-CoV-2 Variants. Telenti A, Hodcroft EB, Robertson DL. Cold Spring Harb Perspect Med 12 a041390 (2022)
  5. SARS-CoV-2-specific T cells in the changing landscape of the COVID-19 pandemic. Bertoletti A, Le Bert N, Tan AT. Immunity 55 1764-1778 (2022)
  6. The past, current and future epidemiological dynamic of SARS-CoV-2. Balloux F, Tan C, Swadling L, Richard D, Jenner C, Maini M, van Dorp L. Oxf Open Immunol 3 iqac003 (2022)
  7. Defending against SARS-CoV-2: The T cell perspective. Almendro-Vázquez P, Laguna-Goya R, Paz-Artal E. Front Immunol 14 1107803 (2023)
  8. Current understanding of T cell immunity against SARS-CoV-2. Lu X, Yamasaki S. Inflamm Regen 42 51 (2022)
  9. SARS-CoV-2 epitopes inform future vaccination strategies. Shafqat A, Omer MH, Ahmad O, Niaz M, Abdulkader HS, Shafqat S, Mushtaq AH, Shaik A, Elshaer AN, Kashir J, Alkattan K, Yaqinuddin A. Front Immunol 13 1041185 (2022)
  10. In search of a pan-coronavirus vaccine: next-generation vaccine design and immune mechanisms. Cankat S, Demael MU, Swadling L. Cell Mol Immunol 21 103-118 (2024)
  11. An Immunological Review of SARS-CoV-2 Infection and Vaccine Serology: Innate and Adaptive Responses to mRNA, Adenovirus, Inactivated and Protein Subunit Vaccines. Al-Sheboul SA, Brown B, Shboul Y, Fricke I, Imarogbe C, Alzoubi KH. Vaccines (Basel) 11 51 (2022)
  12. Innate and adaptive immunity to SARS-CoV-2 and predisposing factors. Shen J, Fan J, Zhao Y, Jiang D, Niu Z, Zhang Z, Cao G. Front Immunol 14 1159326 (2023)
  13. T Cell Epitope Discovery in the Context of Distinct and Unique Indigenous HLA Profiles. Hensen L, Illing PT, Rowntree LC, Davies J, Miller A, Tong SYC, Habel JR, van de Sandt CE, Flanagan KL, Purcell AW, Kedzierska K, Clemens EB. Front Immunol 13 812393 (2022)
  14. SARS-CoV-2 epitope-specific T cells: Immunity response feature, TCR repertoire characteristics and cross-reactivity. Yang G, Wang J, Sun P, Qin J, Yang X, Chen D, Zhang Y, Zhong N, Wang Z. Front Immunol 14 1146196 (2023)
  15. SARS-CoV-2 ORF8 as a Modulator of Cytokine Induction: Evidence and Search for Molecular Mechanisms. Móvio MI, Almeida GWC, Martines IDGL, Barros de Lima G, Sasaki SD, Kihara AH, Poole E, Nevels M, Carlan da Silva MC. Viruses 16 161 (2024)
  16. Employing T-Cell Memory to Effectively Target SARS-CoV-2. Tun ZH, Htike NTT, Kyi-Tha-Thu C, Lee WH. Pathogens 12 301 (2023)
  17. The molecular mechanisms of CD8<sup>+</sup> T cell responses to SARS-CoV-2 infection mediated by TCR-pMHC interactions. Deng S, Xu Z, Hu J, Yang Y, Zhu F, Liu Z, Zhang H, Wu S, Jin T. Front Immunol 15 1468456 (2024)

Articles citing this publication (34)



Quick links